An Open-Label, Randomized Phase II Study of Herceptin (Trastuzumab), Taxotere (Docetaxel), and Xeloda (Capecitabine) in Combination, Versus Herceptin (Trastuzumab) Plus Taxotere (Docetaxel), in Patients With Advanced and/or Metastatic Breast Cancers That Overexpress HER2
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Capecitabine (Primary) ; Docetaxel; Trastuzumab
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms CHAT
- Sponsors Roche
- 23 Feb 2010 Status changed from recruiting to completed as reported by Roche record.
- 28 Dec 2009 Results published in the Journal of Clinical Oncology.
- 16 Feb 2008 Status changed from in progress to completed.